Consultation on the renewal of Federal Tobacco Control Strategy
https://policybase.cma.ca/link/policy13804

POLICY TYPE Response to consultation
DATE 2017-04-05
TOPICS Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents

April 5, 2017

SUBMISSION ON THE FEDERAL TOBACCO CONTROL STRATEGY

Peel Region/ON
Mandepi Kain G Sher, BSc, MD
Director General, Health Outcomes
AstraZeneca

Re: Consultation on the renewal of Federal Tobacco Control Strategy

Dear colleagues,

I am responding to your request for consultation on the renewal of the Federal Tobacco Control Strategy (FTCS), and on the implementation of the first National Tobacco Action Plan (2017-2019).

We welcome the opportunity to contribute to the consultation and to continue to work with the Canadian government towards the goal of reducing overall tobacco use in Canada.

The latest findings from the Canadian Tobacco Use Surveys (CTUS) continue to show that smoking remains the leading preventable cause of disease and premature death in Canada. The toll taken by smoking on health care costs is substantial. The burden of tobacco-related illness is high and is affecting all age groups.

We understand that consultation on the renewal of the strategy will be used to inform the development of a new Federal Tobacco Control Strategy. We would encourage a measured and evidence-based approach in setting priorities and objectives, as well as in the selection of strategies and interventions for implementation.

The Canadian Medical Association (CMA) has been a leading advocate for tobacco control in Canada and has been active in promoting and implementing strategies that address the tobacco epidemic. We are committed to working with all levels of government to reduce the burden of tobacco-related illness and premature death in Canada.

We look forward to working with the Canadian government on the renewal of the Federal Tobacco Control Strategy and hope that it will continue to be a comprehensive and effective approach to addressing the tobacco epidemic.

Sincerely,

Mandepi Kain G Sher, BSc, MD
Director General, Health Outcomes
AstraZeneca

CMA Policybase - Canadian Medical Association